Latest news about Smruthi Organics
Smruthi Organics
122.25
-4.30(-3.40%)
Company Performance:
View Company Insights1D-3.40%
1M+6.21%
6M+9.89%
1Y+3.73%
5Y-63.41%
More news about Smruthi Organics
07Apr 26
Smruthi Organics Limited Files SEBI Compliance Certificate for Q4 FY26
Smruthi Organics Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 ended 31st March, 2026. The certificate from registrar Adroit Corporate Services confirms proper dematerialisation procedures, timely processing of securities, and compliance with depository regulations, demonstrating the company's adherence to corporate governance standards.
09Mar 26
Smruthi Organics Receives CEP Certificate from EDQM for Amlodipine Besilate
Smruthi Organics Limited has successfully received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Amlodipine Besilate product. This achievement completes the regulatory approval process that began with a successful EU GMP compliance inspection at the company's Solapur facility. The CEP certification enables the company to supply Amlodipine Besilate to pharmaceutical manufacturers in European markets and other regions that recognize CEP certification, significantly strengthening its position in regulated markets.
16Feb 26
Smruthi Organics Reports Q3 FY26 Results Following Board Meeting Approval
Smruthi Organics Limited reported Q3 FY26 financial results following Board approval on February 13, 2026. While quarterly net profit declined to ₹139.79 lakhs from ₹148.07 lakhs year-on-year, nine-month performance showed strong growth with 77% increase in net profit to ₹235.87 lakhs. The company recognized an exceptional expense of ₹45.17 lakhs due to new Labour Codes implementation.
05Feb 26
Smruthi Organics Limited Schedules Board Meeting on February 13, 2026 for Q3FY26 Results Approval
Smruthi Organics Limited has scheduled a board meeting on February 13, 2026, to approve unaudited financial results for Q3FY26 ended December 31, 2025. The company notified BSE Limited and Metropolitan Stock Exchange of India Ltd under SEBI Regulation 29. The trading window, closed since January 1, 2026, will remain restricted until 48 hours after the financial results declaration.
11Nov 25
Smruthi Organics Reports Robust Q2 Recovery with Rs 205.62 Crore Net Profit
Smruthi Organics Limited announced unaudited Q2 FY2026 results, showing a significant turnaround with a net profit of Rs 205.62 crore, compared to a loss of Rs 109.54 crore in Q1. Revenue from operations increased to Rs 3,159.52 crore. The API segment remains the major contributor with Rs 5,045.74 crore revenue for the half-year, while the formulations segment reported sales of Rs 21.48 crore but incurred a loss. Total assets stood at Rs 9,963.73 crore with total equity at Rs 7,080.85 crore as of September 30, 2025.
13Aug 25
Smruthi Organics Reports Net Loss of Rs 109.54 Lakhs in Q1
Smruthi Organics, a bulk drugs manufacturer, announced unaudited Q1 results showing a 30.36% year-over-year revenue decline to Rs 1,899.21 lakhs. Net loss widened to Rs 109.54 lakhs from Rs 92.30 lakhs in the previous year. Total expenses of Rs 2,063.30 lakhs exceeded total revenue of Rs 1,907.97 lakhs. The API segment generated Rs 1,893.58 lakhs in revenue with Rs 53.21 lakhs in result before interest and taxes. The Board approved these results on August 13, and auditors Gokhale & Sathe conducted a limited review.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Laurus Labs
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
1,904.00
(+0.21%)
8,570.00
(+0.12%)
5,005.00
(-0.16%)
1,438.00
(+1.13%)
1,107.70
(+0.29%)
2,201.50
(-1.06%)
1,825.00
(+1.29%)
2,385.00
(-0.38%)
1,180.00
(+0.85%)
1,608.00
(-1.02%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
